glp-1/fgf21 agonist boehringer A novel GLP-1 and FGF21 dual has therapeutic potential for diabetes and non-alcoholic steatohepatitis Boehringer Ingelheim, Yuhan Launch Up-to-$870M+
Pay in 4 interest-free payments of $6.58 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28












.png.jpg)















